Abstract
This chapter deals with a variety of clinical conditions in which there is excessive effects of thyroid hormones on the tissues. Hyperthyroidism is the general term, although some workers restrict this to conditions where the thyroid, per se, is overactive. I use hyperthyroidism to imply that there is too much thyroid hormone in the circulation, irrespective of its source. A second term, thyrotoxicosis, literally means ‘toxic’ because of too much thyroid hormone. However, many patients with high serum thyroid levels are not toxic. Nevertheless, in this chapter the two terms are used interchangeably. Most frequently, there are high levels of total hormones and, most often, both T4 and T3 are above normal. On occasion, total hormone values are normal and only the free hormones are high.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Graves, R.J. (1835) London Med. Surg. J., 7 (2), 516.
Parry, C.H. (1825) Collections from the unpublished papers of the late Caleb Hillier Parry, Vol 2, pp. 11–128.
Von Basedow, C.A. (1840) Exophthalmos durch hypertrophie des Zellgewebes in der augenhohle. Wochenschrift Gesummte Heilkunde, 6, 197.
Major, R.H. (1945) Classic Descriptions of Disease: With Biographical Sketches of the Authors, 3rd edn, Charles C Thomas, Springfield.
Taylor, S. (1986) Graves of Graves’ disease, 1796–1853. J. Roy. Coll. Phys., 20, 298–300.
Taylor, S. (1989) Robert Graves: The Golden Years of Irish Medicine, The Royal Society of Medicine, London.
Committee on Nomenclature of the American Thyroid Association (1987) Revised nomenclature for test of thyroid hormones and thyroid-related proteins in the serum. J. Clin. Endocrinol. Metab., 64, 1089–94.
Adams, D.D. and Purves, H.D. (1956) Abnormal responses in the assay of thyrot-rophin. Proc. Univ. Otago Med. Sch., 34, 11–12.
Kriss, J.P., Pleshakov, V. and Chien, J.R. (1964) Isolation and identification of the long-acting thyroid stimulator and its relation to hyperthyroidism and circumscribed pretibial myxedema. J. Clin. Endocrinol. Metab., 24, 1005–28.
McKenzie, J.M. (1958) Delayed thyroid response to serum from thyrotoxic patients. Endocrinol, 62, 865–8.
Kriss, J.P. (1968) The long-acting thyroid stimulator. Calif. Med., 109, 202–13.
Ochi, Y. and DeGroot, L.J. (1968) Long acting thyroid stimulator of Graves’s disease. N. Engl. J. Med., 278, 718–21.
Adams, D.D. and Kennedy, T.H. (1967) The occurrence in thyrotoxicosis of a gamma globulin which protects LATS from neutralisation by an extract of thyroid gland. J. Clin. Endocrinol. Metab., 27, 173–7.
Adams, D.D. (1988) Long-acting thyroid stimulator: how receptor autoimmunity was discovered. Autoimmunity, 1, 3–9.
Adams, D.D., Fastier, F.N., Howie, J.B. et al. (1974) Stimulation of the human thyroid by infusions of plasma containing LATS protector. J. Clin. Endocrinol. Metab., 39, 826–32.
Zakarija, M., McKenzie, J.M. and Banovac, K. (1980) Clinical significance of thyroid-stimulating antibody in Graves’ disease. Ann. Intern. Med., 93, 28–32.
McKenzie, J.M. (1980) Thyroid-stimulating antibody (TSAb) in Graves’ disease. Thyroid Today, (ed. J.H. Oppenheimer) 2 (5), 1–5.
Morris, J.C. III. Hay, I.D., Nelson, R.E. et al. (1988) Clinical utility of thyrotropin-receptor antibody assays: comparison of radioreceptor and bioassay methods. Mayo Clin. Proc., 63, 707–17.
Wilson, R., McKillop, J.H., Pearson, D.W.M. et al. (1985) Relapse of Graves’ disease after medical therapy: predictive value of thyroidal technetium-99m uptake and serum thyroid stimulating hormone receptor antibody levels. J. Nucl. Med., 26, 1024–8.
Madec, A.M., Laurent, M.C., Lorcy, Y. et al. (1984) Thyroid-stimulating antibodies: an aid to the strategy of treatment of Graves’ disease? Clin. Endocrinol., 21; 247–55.
Rees-Smith, B. (1988) Autoantibodies to the thyrotropin receptor. Endocrine Rev., 9, 106–21.
Munro, D.S., Dirmikis, S.M., Humphries, H. et al. (1978) The role of thyroid-stimulating immunoglobulins of Graves’ disease in neonatal thyrotoxicosis. Br. J. Obstet. Gyn., 85, 837–43.
Volpé, R. (1981) Auto-immunity in the endocrine system. Monograph Endocrinol., 20, 19–111.
Strakosch, C.R., Wenzel, B.E., Row, V.V. et al (1982) Immunology of autoimmune thyroid disease. N. Engl. J. Med., 307; 1499–504.
Bartrop, R.W., Lockhurst, E., Lazarus, L. et al. (1977) Depressed lymphocyte function after bereavement. Lancet, 1, 834–6.
Wilson, G.M. (1967) The Treatment of Thyrotoxicosis, Symposium Thyroid Disease and Calcium Metabolism, Royal College of Physicians, Edinburgh, pp. 51–76.
Wasnich, R.D., Grumet, F.C., Payne, R.O. et al. (1973) Graves’ ophthalmopathy following external neck irradiation for nonthyroidal neoplastic disease. J. Clin. Endocrinol Metab., 37, 703–13.
Davis, P.J., Rappeport, J.R., Lutz, J.H. et al. (1971) Three thyrotoxic criminals. Ann. Intern. Med., 74, 734–5.
Rockey, P.H. and Griep, R.J. (1980) Behavioral dysfunction in hyperthyroidism: improvement with treatment. Arch. Intern. Med., 149, 1194–7.
Rothberg, M.P., Shebert, R.T., Levey, G.S. et al. (1974) Propranolol and hyperthyroidism: reversal of upper motor signs. JAMA, 230, 1017.
Okinaka, S., Shizume, K., Lino. S. et al. (1957) The association of periodic paralysis and hyperthyroidism in Japan. J. Clin. Endocrinol Metab., 17, 1454–9.
Dyde, J.A. (1965) Hyperthyroidism complicated by periodic paralysis. Postgrad. Med. J., 41, 286–7.
Barnard, J.D., Larson, M.A., Norris, F.H. Jr (1972) Thyrotoxic periodic paralysis in Cali-fornians of Mexican and Filipino ancestry. Calif. Med., 116, 70–4.
Leung, A.K.C. (1985) Familial ‘hashitoxic’ periodic paralysis. J. Roy. Soc. Med., 78, 638–40.
Sum, C.F., Fok, A.C.K., Tan, K.T. et al. (1988) Human leucocyte antigen in a Chinese family with thyrotoxic periodic paralysis in Singapore. Br. Med. J., 297, 594–5.
McFadzean, A.J.S. and Yeung, R. (1967) Periodic paralysis complicating thyrotoxicosis in Chinese. Br. Med. J., 1, 451–5.
Ober, K.P. and Hennessey, J.F. (1981) Jod Basedow and thyrotoxic periodic paralysis. Arch, Intern. Med., 141, 1225–7.
Layzer, R.B. and Goldfield, E. (1974) Periodic paralysis caused by abuse of thyroid hormone. Neurol., 24, 949–52.
Edelman, J. and Stewart-Wynne, E.G. (1981) Respirarory and bulbar paralysis with relapsing hyperthyroidism. Br. Med. J., 283, 275–6.
Guthrie, G.P. Jr, Curtis, J.J. and Beilman, K.M. (1978) Hypophosphatemia in thyrotoxic periodic paralysis. Arch. Intern. Med., 138, 1284–5.
Feely, J. (1981) Potassium shift in thyrotoxic periodic paralysis. Postgrad. Med. J., 57, 238–9.
Yeung, R.T.T. and Tse, T.F. (1974) Thyrotoxic periodic paralysis: effect of propranol. Am. J. Med., 57, 584–90.
Ramsay, I. (1966) Muscle dysfunction in hyperthyroidism. Lancet, 3, 931–5.
Drachman, D.B. (1962) Myasthenia gravis and the thyroid gland. N. Engl. J. Med., 266, 330–3.
Muggia, A.L., Stjernholm, M. and Houle, T. (1970) Complete heart block with thyrotoxic myocarditis; report of a case. N. Engl. J. Med., 283, 1099–100.
Campus, S., Rappelli, A., Malavasi, A. et al. (1975) Heart block and hyperthyroidism: report of two cases. Arch. Intern. Med., 135, 1091–5.
Stern, M.P., Jacobs, R.L., and Duncan, G.W. (1970) Complete heart block complicating hyperthyroidism. JAMA, 212, 2117–19.
Eraker, S.A., Wickamasekaran, R. and Goldman, S. (1978) Complete heart block with hyperthyroidism. JAMA, 239, 1644–6.
Wei, J.Y., Genecin, A., Greene, H.L. et al. (1979) Coronary spasm with ventricular fibrillation during thyrotoxicosis: response to attaining euthyroid state. Am. J. Cardiol., 43, 335–9.
Featherstone, H.J. and Stewart, D.K. (1983) Angina in thyrotoxicosis: thyroid-related coronary artery spasm. Arch. Intern. Med., 143, 554–5.
Kotler, M.N., Michaelides, K.M., Bouchard, R.J. et al. (1973) Myocardial infarction associated with thyrotoxicosis. Arch. Intern. Med., 132, 723–8.
Cobler, J.L., Williams, M.E. and Greenland, P. (1984) Thyrotoxicosis in institutionalised elderly patients with atrial fibrillation. Arch. Intern. Med., 144, 1758–60.
Williams, R.H. (1946) Thiouracil treatment in thyrotoxicosis. J. Clin. Endocrinol. Metab., 41, 354–61.
Mornex, R. and Orgiazzi, J.J. (1980) Hyperthyroidism, in The Thyroid Gland, (ed. M. De Visscher), Raven Press, New York, pp. 279–63.
Wayne, E.J. (1954) The diagnosis of thyrotoxicosis. Br. Med. J., 1, 411–19.
Bar-Sela, S., Ehrenfeld, M. and Eliakim, M. (1981) Arterial embolism in thyrotoxicosis with atrial fibrillation. Arch. Intern. Med., 141, 1191–2.
Hausmann, W. (1974) Thyrotoxic cardiomyopathy complicated by systemic and pulmonary embolism. Proc. Roy. Soc. Med., 68, 327.
Giddings, H.B. and Surks, M.I. (1978) Cerebral embolization in atrial fibrillation complicating hyperthyroidism. JAMA, 240, 2567–8.
Staffurth, J., Gibberd, M., Tang Fui, S.N. (1977) Arterial embolism in thyrotoxicosis with atrial fibrillation. Br. Med. J., 2, 688–90.
Forfar, J.C., Miller, H.C. and Toft, A.D. (1979) Occult thyrotoxicosis: a correctable cause of idiopathic atrial fibrillation. Am. J. Cardiol, 44, 9–12.
Parker, J.L.W. and Lawson, D.H. (1973) Death from thyrotoxicosis. Lancet, 2, 894–5.
Magner, J.A., Clark, W. and Allenby, P. (1988) Congestive heart failure and death in a young woman with thyrotoxicosis. West J. Med., 149, 86–91.
Rosenthal, F.D., Jones, C. and Lewis, S.I. (1977) Thyrotoxic vomiting. Br. Med. J., 2, 209–11.
Parkin, A.J., Nisbet, A.P. and Bishop, N. (1981) Vomiting due to gastric stasis as the presenting feature in thyrotoxicosis. Postgrad. Med. J., 57, 405.
Miller, L.J., Gorman, C.A. and Go, V.L.W. (1978) Thyroid-gut interrelationships. Gastroenterology, 75, 901–11.
Ashkar, F.S., Miller, R., Smoak, W.M. et al. (1971) Liver disease in hyperthyroidism. South Med. J., 64, 462–5.
Marks, P. and Ashraf, H. (1978) Apathetic hyperthyroidism with hypomagnesaemia and raised alkaline phosphatase concentration. Br. Med. J., 1, 821–2.
Herbert, V. (1986) The blood, in Werner’s The Thyroid, 5th edn, (eds S.H. Ingbar and L.E. Braverman), J.B. Lippincott Company, Philadelphia, pp. 878–84.
Dunlap, D.B., McFarland, K.F. and Lutcher, C.L. (1974) Graves’ disease and idiopathic thrombocytopenic purpura. Am. J. Med. Sci., 268, 107–11.
Grish, L.S. and Meyerson, R.M. (1957) Thyrotoxicosis associated with thrombocytopenia and hypersplenism. Am. J. Clin. Pathol., 27, 328–31.
Hymes, K., Blum, M., Lackner, H. et al. (1981) Easy bruising, thrombocytopenia, and elevated platelet immunoglobulin G in Graves’ disease and Hashimoto’s thyroiditis. Ann. Intern. Med., 94, 27–30.
Irvine, W.J., Wu, F.C.W., Urbaniac, S.J. et al. (1977) Peripheral blood leukocytes in thyrotoxicosis (Graves’) disease as studied by conventional light microscopy. Clin. Exp. Immunology, 27, 216–21.
Wall, J.R., Gray, B. and Greenswood, D.M. (1977) Total and activated peripheral blood T-lymphocytes in patients with Graves’ disease. Acta Endocrinol., 85, 753–9.
Van Herle, A.J. and Chopra, I.J. (1971) Thymic hyperplasia in Graves’ disease. J. Clin. Endocrinol. Metab., 32, 140–6.
Mahaux, J.E., Chamla-Soumenkoff, J., Delcourt, R. et al. (1971) Painful enlargement of left subtrapezoid lymph nodes in Graves’ disease. Br. Med. J., 1, 384.
Baxter, J.D. and Bondy, P.K. (1966) Hypercalcemia of thyrotoxicosis. Ann. Intern. Med., 65, 429–42.
Mallette, L.E. and Tuma, S.N. (1984) A new radioimmunoassay for the midregion of canine parathyroid hormone. Mineral Electrol. Metabol., 10, 43–7.
Mallette, L.E., Rubenfeld, S. and Silverman, V. (1985) A controlled study of the effects of thyrotoxicosis and propranolol treatment on mineral metabolism and parathyroid hormone immunoreactivity. Metabolism, 34, 999–1006.
Cooper, D.S., Kaplan, M.M., Ridgway, E.C. et al. (1979) Alkaline phosphatase isoenzyme patterns in hyperthyroidism. Ann. Intern. Med., 90, 164–8.
Arem, R., Lim-Abrahan, M.A. and Mallette, L.E. (1986) Concomitant Graves’ disease and primary hyperthyroidism: influence of hyperthyroidism on serum calcium and parathyroid hormone. Am. J. Med., 80, 693–8.
Christensson, T. (1977) Hyperparathyroidism and radiation therapy. Ann. Intern. Med., 89, 216–17.
Rao, S.D., Frame, B., Miller, M.J. et al. (1980) Hyperparathyroidism following head and neck irradiation. Arch. Intern. Med., 140, 205–7.
Rosen, I.B., Palmer, J.A., Rowen, J. et al. (1984) Induction of hyperparathyroidism by radioactive iodine. Am. J. Surg., 148, 441–5.
Fraser, S.A., Smith, D.A., Anderson, J.B. et al. (1975) Osteoporosis and fractures following thyrotoxicosis. Lancet, 1, 981–3.
Fallon, M.D., Perry, H.M. III, Bergfeld, M. et al. (1983) Exogenous hyperthyroidism with osteoporosis. Arch. Intern. Med., 143, 442–4.
Ross, D.S., Neer, R.M., Ridgway, E.C. et al. (1987) Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary thyroid axis with L-thyroxine. Am. J. Med., 82, 1167–70.
Auwerx, J. and Bouillon, R. (1986) Mineral and bone metabolism in thyroid disease: a review. Quart. J. Med., 232, 737–52.
Clyde, H.R., Walsh, P.C. and English, R.W. (1976) Elevated plasma testosterone and gonadotropin levels in infertile males with hyperthyroidism. Fertil. Steril., 27, 662–6.
Becker, K.L., Winnacker, J.L., Matthews, M.J. et al. (1968) Gynecomastia and hyperthyroidism. An endocrine and histologic investigation. J. Clin. Endocrinol Metab., 28, 277–85.
Morgans, M.E. (1964) Hyperthyroidism, in The Thyroid Gland, Vol 2, (eds R.V. Pitt-Rivers and W.R. Trotter), Butterworth, London, p. 159.
Ochi, Y. and DeGroot, L.J. (1969) Vitiligo in Graves’ disease. Ann. Intern. Med., 71, 935–40.
Wyse, E.P., McConahey, W.M., Woolner, L.B. et al. (1968) Ophthalmopathy without hyperthyroidism in patients with histologic Hashimoto’s thyroiditis. J. Clin. Endocrinol. Metab., 28, 1623–9.
Rundle, F.F. and Pochin, E.E. (1944) The orbital tissues in thyrotoxicosis: a quantitative analysis relating to exophthalmos. Clin. Sci., 5, 51–74.
Hufnagel, T.J., Hickey, W.F., Cobbs, W.H. et al. (1984) Immunohistochemical and ultra-structural studies on the exenterated orbital tissues of a patient with Graves’ disease. Ophthalmology, 91, 1411–19.
Werner, S.C., Coleman, D.J. and Franzen, L.A. (1974) Ultrasonographic evidence of a consistent orbital involvement in Graves’ disease. N. Engl. J. Med., 290, 1447–50.
Forrester, J.V., Sutherland, G.R. and McDougall, I.R. (1977) Dysthroid ophthalmopathy orbital evaluation with B-scan ultrasonography. J. Clin. Endocrinol. Metab., 45, 1353–6.
Enzmann, D.R., Donaldson, S.S. and Kriss, J.P. (1979) Appearance of Graves’ disease on orbital computed tomography. J. Comput. Assist. Tomogr., 3, 815–19.
Konishi, J., Hermann, M.M. and Kriss, J.P. (1974) Binding of thyroglobulin and thyroglobulin-antithyroglobulin immune complex to extraocular muscle membranes. Endocrinol., 95, 434–6.
Tao, T.W., Cheng, P., Pham, H. et al. (1986) Monoclonal antithyroglobulin antibodies derived from immunisation of mice with human eye muscle and thyroid membranes. J. Clin. Endocrinol. Metab., 63, 577–82.
Kriss, J.P. (1970) Radioiosotope thyroidolymphography in patients with Graves’ disease. J. Clin. Endocrinol. Metab., 31, 315–24.
Werner, S.C. (1969) Classification of the eye changes of Graves’ disease. J. Clin. Endocrinol. Metabol., 29, 982–4.
Donaldson, S.S., Bagshaw, M.A. and Kriss, J.P. (1973) Supervoltage orbital radiotherapy for Graves’ ophthalmopathy. J. Clin. Endocrinol. Metab., 37, 276–85.
Gorman, C.A. (1983) Temporal relationship between onset of Graves’ ophthalmopathy and diagnosis of thyrotoxicosis. Mayo Clin. Proc., 58, 515–19.
Marcocci, C., Bartalena, L., Bogazzi, F. et al. (1989) Studies on the occurrence of ophthalmopathy in Graves’ disease. Acta Endocrinol., 120, 473–8.
Kriss, J.P., McDougall, I.R., Donaldson, S.S. (1987) Non-thyroidal complications of Graves’ disease: perspective on pathogenesis and treatment, in Thyroid Autoimmunity, (eds A. Pinchera, S.H. Ingbar, J.M. McKenzie and G.F. Fenzi), Plenum Publishing Corporation, New York and London, pp. 263–9.
Kriss, J.P., Petersen, I.A., Donaldson, S.S. et al. (1989) Supervoltage orbital radiotherapy for progressive Graves’ ophthalmopathy: results of a twenty year experience. Acta Endocrinol., 121 (suppl. 2), 154–9.
Gwinup, G., Elias, A.N. and Ascher, A.S. (1982) Effect on exophthalmos of various treatment methods of Graves’ disease. JAMA, 247, 2135–8.
Sridama, V. and De Groot, L.J. (1989) Treatment of Graves’ disease and the course of ophthalmopathy. Am. J. Med., 87, 70–3.
De Juan, E., Hurley, D.B. and Sapira, J.D. (1980) Racial differences in normal values of proptosis. Arch. Intern. Med., 140, 1230–1.
Gamblin, G.T., Harper, D.G., Galentine, P. et al. (1983) Prevalence of increased intraocular pressure in Graves’ disease — evidence of frequent subclinical ophthalmopathy. N. Engl. J. Med., 308, 420–4.
Werner, S.C. (1966) Prednisone in emergency treatment of malignat exophthalmos. Lancet, 1, 1004–7.
Prummel, M.F., Mouritis, M.P.H., Berghout, A. et al. (1989) Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N. Engl. J. Med., 321, 1353–9.
Jones, A. (1951) Orbital X-ray therapy of progressive exophthalmos. Br. J. Radiol., 29, 637–46.
Ogura, J.H., Wessler, S. and Avioli, L.V. (1971) Surgical approach to the ophthalmopathy of Graves’ disease. JAMA, 216, 1627–31.
Ogura, J.H. and Lucente, F.E. (1974) Surgical results of orbital decompression for malignant exophthalmos. Laryngoscope, 84, 637–44.
McCord, CD. Jr (1981) Orbital decompression for Graves’ disease: exposure through lateral canthal and inferior fornix incision. Ophthalmology, 88, 533–41.
Wolfe, S.A. (1977) A rationale for the surgical treatment of exophthalmos and exorbitism. J. Maxillo-facial Surg., 5, 249–57.
Wolfe, S.A. (1978) Modified three-wall orbital expansion to correct persistent exophthalmos or exorbitism. Plastic and Reconstruct. Surg., 64, 448–55.
Utech, C., Cordes, M., Pfannensteil, P. et al. (1987) Immunosuppressive treatment of Graves’ ophthalmopathy with cyclosporin A and ciamexon, in Thyroid Autoimmunity, (eds A. Pinchera, S.H. Ingbar, J.M. McKenzie and G.F. Fenzi), Plenum Press, New York and London, pp. 541–4.
Dandona, P., Marshall, N.J., Bidey, S.P. et al. (1979) Successful treatment of exophthalmos and pretibial myxoedema with plasm-pheresis. Br. Med. J., 1, 374–6.
Catz, B. and Perzik, S.L. (1969) Total thyroidectomy in the management of thyrotoxic and euthyroid Graves’ disease. Am. J. Surg., 118, 434–9.
Kriss, J.P. (1980) Pathogenesis and treatment of Graves’ ophthalmopathy. Thyroid Today7 (2), 1–7.
Jacobson, D.H. and Gorman, C.A. (1984) Endocrine ophthalmopathy: current ideas concerning etiology, pathogenesis, and treatment. Endocrin. Rev., 5, 200–20.
Shine, B., Edwards, O.M. and Weetman, A. P. (1989) Graves’ ophthalmopathy and smoking. Acta Endocrinol., 121 (suppl. 2), 182–4.
Austin-Seymour, M.M., Donaldson, S.S., Egbert, P.R. et al. (1985) Radiotherapy of lymphoid diseases of the orbit. Int. J. Radiât. Oncol. Biol. Phys., 11, 371–9.
Kriss, J.P. (1987) Pathogenesis and treatment of pretibial myxedema. Endocrinol. Metab. Clin. N. Am., 16, 409–15.
Cheung, H.S., Nicoloff, J.T., Kamiel, M.B. et al. (1978) Stimulation of fibroblast biosynthetic activity by serum of patients with pretibial myxedema. J. Invest. Dermatol., 71, 12–17.
Sissons, J.C. (1968) Hyaluronic acid in localised myxedema. J. Clin. Endocrinol. Metab., 28, 433–41.
Kriss, J.P., Pleshakov, V., Rosenblum, A. et al. (1967) Therapy with occlusive dressings of pretibial myxedema with fluocinolone aceto-nide. J. Clin. Endocrinol. Metab., 27, 595–604.
Freedberg, I.M. and Vogel, L.N. (1986) The skin, in Werner’s The Thyroid, 5th edn, (eds S.H. Ingbar and L.E. Braverman), The Lip-pincott Company, Philadelphia, pp. 811–16.
Goette, D.K. (1980) Thyroid acropachy. Arch. Dermatol., 116, 205–6.
Gimlette, T.M.D. (1960) Thyroid acropachy. Lancet, 1, 22–4.
Thomas, H.M. Jr (1933) Acropachy: secondary subperiosteal new bone formation. Arch. Intern. Med., 51, 571–87.
Nixon, D. and Samols, E. (1970) Acral changes associated with thyroid diseases. JAMA, 212, 1175–81.
Diamond, M.T. (1959) The syndrome of exophthalmos, hypertrophic osteoarthropathy and localized myxedema: A review of the literature and report of a case. Ann. Intern. Med., 50, 206–19.
Parker, L.N., Wu, S-Y., Lai, M.K. et al. (1982) The early diagnosis of atypical thyroid acropachy. Arch. Intern. Med., 142, 1749–51.
Siegel, R., Thrall, J. and Sisson, J. (1976) 99mTc-pyrophosphate scan and radiographic correlation in thyroid acropachy: case report. J. Nucl. Med., 17, 791–3.
Engel, A.G. (1984) Myasthenia and myasthenic syndromes. Ann. Neurol., 16, 519–34.
Naqui, J. (1967) Co-existence of Addison’s disease and thyrotoxicosis. Postgrad. Med. J., 43, 129.
Goldring, S.R. and Krane, S.M. (1986) The skeletal system, in Werner’s The Thyroid, 5th edn, (eds S.H. Ingbar and L.E. Braverman) The Lippincott Company, Philadelphia, pp. 930–48.
Ross, D.S. (1988) Subclinical hyperthyroidism: possible danger of overzealous thyroxine replacement therapy. Mayo Clin. Proc., 63, 1223–9.
Wilson, G.M. (1967) The treatment of thyrotoxicosis, Symposium Thyroid Disease and Calcium Metabolism, Royal College of Physicians, Publication 33, Edinburgh, pp. 51–76.
Taurog, A. (1976) The mechanism of action of the thioureylene antithyroid drugs. Endocrinol., 98, 1031–46.
Marchant, B., Lees, J.F.H. and Alexander, W.D. (1978) Antithyroid drugs. Pharmacol. Ther. B., 3, 305–48.
Lazarus, J.H., Marchant, B., Alexander, W.D. et al. (1975) 35S-antithyroid drug concentration and organic binding of iodine in the human thyroid. Clin. Endocrinol., 4, 609–15.
Cooper, D.S. (1986) Which antithyroid drug? Am. J. Med., 80, 1165–8.
Bouma, D.J. and Kammer, H. (1980) Single daily dose methimazole treatment of hyperthyroidism. West J. Med., 132, 13–15.
MacFarlane, I.A., Davies, D., Longson, D. et al. (1983) Single daily dose short term Carbimazole therapy for hyperthyroid Graves’ disease. Clin. Endocrinol., 18, 557–61.
Gwinup, G. (1978) Prospective randomized comparison of propylthiouracil. JAMA, 239, 2457–9.
McDougall, I.R. and Greig, W.R. (1972) Combined carbimazole-131I therapy for thyrotoxicosis. Scot. Med. J., 17, 57–61.
Crooks, J. and Wayne, E.J. (1960) A comparison of potassium perchlorate, methyl-thiouracil and Carbimazole in the treatment of thyrotoxicosis. Lancet, 1, 401–4.
Cooper, D.S. (1985) Propylthiouracil levels in hyperthyroid patients unresponsive to large doses: evidence of poor patient compliance. Ann. Intern. Med., 102, 328–31.
Wood, L.C., Peterson, M. and Ingbar, S.H. (1972) Delayed hypothyroidism following antithyroid therapy in Graves’ disease Clin. Res., 20, 625.
Solomon, B.L., Evaul, J.E., Burman, K.D. et al. (1987) Remission rates with antithyroid drug therapy: continuing influence of iodine intake? Ann. Intern. Med., 102, 510–12.
Alexander, W.D., Harden, R. McG., Koutras, D.A. et al. (1965) Influence of iodine intake after treatment with antithyroid drugs. Lancet, 2, 866–8.
Wartofsky, L. (1973) Low remission after therapy for Graves’ disease: possible relation of dietary iodine with antithyroid drugs. JAMA, 226, 1083–8.
Greer, M.A., Kammer, H. and Bouma, D.J. (1977) Short-term antithyroid drug therapy for the thyrotoxicosis of Graves’ disease. N. Engl. J. Med., 297, 173–6.
Burr, W.A., Fitzgerald, M.G. and Hoffen-berg, R. (1979) Relapse after short-term antithyroid therapy of Graves’ disease. N. Engl. J. Med., 300, 200.
Slingerland, D.W. and Burrows, B.A. (1979) Long-term antithyroid treatment in hyperthyroidism. JAMA, 242, 2408–10.
Cooper, D.S. (1984) Antithyroid drugs. N. Engl. J. Med., 311, 1353–62.
Rosove, M.H. (1977) Agranulocytosis and antithyroid drugs. West J. Med., 126, 339–43.
Cooper, D.S., Goldminz, D., Levin, A.A. et al. (1983) Agranulocytosis associated with antithyroid drugs: effects of patient age and drug dose. Ann. Intern. Med., 98, 26–9.
International agranulocytosis and aplastic anaemia study (1980) Risk of agranulocytosis and aplastic anaemia in relation to use of antithyroid drugs. Br. Med. J., 297, 262–5.
Weiss, M., Hassin, D. and Bank, H. (1980) Propylthiouracil-induced hepatic damage. Arch. Intern. Med., 140, 1184–5.
Hanson, J.S. (1984) Propylthiouracil and hepatitis: two cases and a review of the literature. Arch. Intern. Med., 144, 994–6.
Orrego, H., Blake, J.E., Blendis, L.M. et al. (1987) Long-term treatment of alcoholic liver disease with propylthiouracil. N. Engl. J. Med., 317, 1421–7.
Mazzaferri, E.L., Reynolds, J.C., Young, R.L. et al. (1976) Propranolol as primary therapy for thyrotoxicosis. Results of a long-term prospective trial. Arch. Intern. Med., 136, 50–6.
Jones, M.K., Birthwell, J., Owens, D.R. et al. (1981) Beta-adrenergic blocking drugs and thyroid hormones in hyperthyroid subjects. Postgrad. Med. J., 57, 207–9.
Eriksson, M., Rubenfeld, S., Garber, A.J. et al. (1977) Propranolol does not prevent thyroid storm. N. Engl. J. Med., 296, 263–4.
Rubenfeld, S., Silverman, V.E., Welch, K.M.A. et al. (1979) Variable plasma propranolol levels in thyrotoxicosis. N. Engl. J. Med., 300, 353–4.
Burrow, G.N., Burke, W.R., and Himmelhoch, J.M. (1971) Effect of lithium on thyroid function. J. Clin. Endocrinol. Metab., 32, 647–52.
James, R.J. and Darken, R.A. (1976) Lithium carbonate and hypothyroidism. Med. J. Aust., 1, 266–7.
Spaulding, S.W., Burrow, G.N., Bermudez, F. et al. (1972) The inhibitory effect of lithium on thyroid hormone release in both euthyroid and thyrotoxic patients. J. Clin. Endocrinol. Metab., 35, 905–11.
Kristensen, O., Andersen, H.H. and Pallis-gaard, G. (1976) Lithium carbonate in the treatment of thyrotoxicosis: a controlled trial. Lancet, 1, 603–5.
Turner, J.C. and Brownlie, B.E.W. (1976) Lithium and thyrotoxicosis, Lancet, 2, 904.
Turner, J.G., Brownlie, B.E.W., Rogers, T.G.H. (1976) Lithium as an adjuvant to radioiodine therapy for thyrotoxicosis, Lancet, 1, 614–15.
Hertz, S. and Roberts, A. (1942) Application of radioactive iodine in the therapy of Graves’ disease. J. Clin, Invest., 26, 624.
Hamilton, J.G. and Lawrence, J.H. (1942) Recent clinical developments in the therapeutic application of radiophosphorus and radioiodine. J. Clin. Invest., 26, 624.
Chapman, E.M. (1983), History of the discovery and early use of radioactive iodine. JAMA, 250, 2042–4.
Chapman, E.M. and Evans, R.D. (1946) The treatment of hyperthyroidism with radioactive iodine. JAMA, 131, 86–91.
Greig, W.R., Smith, J.F.B., Gillespie, F.C. et al. (1969) Iodine-125 for thyrotoxicosis, Lancet, 1, 755–7.
Chapman, E.M. and Maloof, F. (1955) The use of radioactive iodine in the diagnosis and treatment of hyperthyroidism: ten years’ experience. Medicine, 34, 261–321.
Beling, U. and Einhorn, J. (1961) Incidence of hypothyroidism and recurrences following 131I treatment of hyperthyroidism. Acta Radiologica, 56, 275–88.
Green, M. and Wilson, G.M. (1964) Thyrotoxicosis treated by surgery or 131I: with special reference to the development of hypothyroidism. Br. Med. J., 1, 1005–10.
Dunn, J.T. and Chapman, E.M. (1964) Rising incidence of hypothyroidism after radioactive iodine. N. Engl. J. Med., 271, 1037–42.
Nofal M.M., Beierwaltes, W.H. and Patno, M.E. (1966) Treatment of hyperthyroidism with sodium iodide 131I. JAMA, 197, 605–10.
Bronsky, D., Kiamko, R.T. and Waldstein, S.S. (1968) Post-therapeutic myxedema. Arch. Intern. Med., 121, 113–17.
Blahd, W.H. and Hays, M.T. (1972) Graves’ disease in the male. Arch. Intern. Med., 129, 33–40.
Teczan, U.P., Frelick, R.N. and Mecklenburg, R.C. (1967) Low dose therapy for hyperthyroidism. Del Med. J., 39, 142–6.
Zellman, H.E., Matiz, H., Bartels, E.C. et al. (1968) Radioactive iodine in hyperthyroidism Lahey Clin. Foun. Bull, 17, 137–43.
Goolden, A.N.C. and Fraser, T.R. (1969) Treatment of thyrotoxicosis with low doses of radioactive iodine. Br. Med. J., 3, 442–3.
Rapoport, B., Caplan, R. and DeGroot, L.J. (1973) Low-dose sodium iodideI-131 therapy in Graves’ disease. JAMA, 224, 1610–13.
Cevallos, J.L., Hagen, G.A., Maloof, F. et al. (1974) Low-dosage 131I therapy of thyrotoxicosis (diffuse goiters). N. Engl. J. Med., 290, 141–3.
Lowe, D.C., Montgomery, D.A.D., Hadden, D.R. et al. (1971) Hyperthyroidism treated with propranolol and a 2.5 millicurie dose of radioactive iodine, Paper 18, Fourth European Thyroid Association Meeting, Berne, Switzerland.
Von Hofe, S.E., Dorfman, S.G., Carretta, R.F. et al. (1978) The increasing incidence of hypothyroidism within one year after radioiodine therapy for toxic diffuse goiter. J. Nucl. Med., 19, 180–4.
Kendall-Taylor, P., Keir, M.J. and Ross, W.M. (1984) Ablative radioiodine therapy for hyperthyroidism: long term follow up study. Br. Med. J., 289, 361–3.
Roudebush, C.P., Hoye, K.E. and DeGroot, L.J. (1977) Compensated low-dose 131I therapy of Graves’ disease. Ann. Intern. Med., 87, 441–3.
Scott, G.R., Forfar, J.C. and Toft, A.D. (1984) Graves’ disease and atrial fibrillation: the case for even higher doses of therapeutic iodine-131. Br. Med. J., 289, 399–400.
Cunnien, A.J., Hay, I.D., Gorman, C.A. et al. (1982) Radio-iodine induced hypothyroidism in Graves’ disease: factors associated with the increasing incidence. J. Nucl. Med., 23, 978–83.
Sridama, V., McCormick, M., Kaplan, E.L. et al. (1984) Long-term follow-up of compensated low-dose 131I therapy for Graves’ disease. N. Engl. J. Med., 311, 426–32.
Smith, R.N. and Wilson, G.M. (1967) Clinical trial of different doses of 131I in the treatment of thyrotoxicosis. Br. Med. J., 1, 129–32.
Holm, I.-E., Lundell, G., Israelsson, A. et al. (1982) Incidence of hypothyroidism occurring long after iodine-131 therapy for hyperthyroidism. J. Nucl. Med., 23, 103–7.
Holm, I.-E. (1982) Changing annual incidence of hypothyroidism after iodine-131 therapy for hyperthyroidism. 1951–75. J. Nucl. Med., 23, 108–12.
Staffurth, J.S. (1987) Hypothyroidism following radioiodine treatment of thyrotoxicosis. J. Roy. Coll, Phys., 21, 55–7.
Shafer, R.B. and Nuttall, F.Q. (1971) Thyroid crisis induced by radioactive iodine. J. Nucl. Med., 12, 262–4.
Hayek, A. (1978) Thyroid storm following radioiodine for thyrotoxicosis. J. Pediatrics, 93, 978–80.
McDermott, M.T., Kidd, G.S., Dodson, L.E. Jr. et al. (1983) Radioiodine-induced thyroid storm: case report and literature review. Am. J. Med., 75, 353–9.
Crooks, J., Buchanan, W.W., Wayne, E.J. et al. (1960) Effect of pretreatment with methyl-thiouracil on results of 131I therapy. Br. Med. J., 1, 151–4.
Steinbach, J.J., Donoghue, G.D., Goldman, J.K. (1979) Simultaneous treatment of toxic diffuse goiter withI-131 and antithyroid drugs: a prospective study. J. Nucl. Med., 20, 1263–7.
Cassidy, C.E. and Astwood, E.B. (1959) Evaluation of radioactive iodine (131I) as a treatment for thyrotoxicosis. N. Engl. J. Med., 261, 53–8.
Sheeler, L.B. and Skillern, P.G. (1984) Radioiodine-induced thyroid storm, a point of controversy (letter). Am. J. Med., 76, A69.
Volpe, R., Schatz, D.L., Scott, A. et al. (1960) Radioactive iodine in the treatment of hyperthyroidism. Can. Med. Ass.]., 83, 1407–13.
Goolden, A.W., Mallard, J.R. and Farran, H.E.A. (1957) Radiation sialitis following radioiodine therapy. Br. J. Radiol., 30, 210–12.
Rigler, R.G. and Scanion, P.W. (1955) Radiation parotitis from radioactive iodine therapy. Mayo Clin. Proc., 30, 149–53.
Silver, S. (1968) Treatment of hyperthyroidism with 131I, in Radioactive Nuclides in Medicine and Biology, vol 2, 3rd edn, Lea and Febiger, Philadelphia, pp. 144–94.
Snyder, S. (1978) Vocal cord paralysis after radioidine therapy. J. Nucl. Med., 19, 975–6.
Robson, A.M. (1981) Vocal-cord paralysis after treatment of thyrotoxicosis with radioidine. Br. J. Radiol., 54, 632.
Freeman, M., Giuliani, M., Schwartz, E. et al. (1969) Acute thyroiditis, thyroid crisis, and hypocalcemia following radioactive iodine therapy. N.Y. State J. Med., 69, 2036–41.
Gilbert-Dreyfus, Zara M., Gali, P. (1958) Cateracte tétanique après IRA-thérapie. Semaine Hop. Paris, 34, 1301–4.
Townsend, J. (1962) Hypoparathyroidism following radioactive iodine therapy for intractable angina pectoris. Ann. Intern. Med., 55, 662–3.
Committee on the Biological Effects of Ionizing Radiation (1980) The Effects on Populations of Exposure to Low Levels of Ionizing Radiation, National Academy of Sciences, Washington DC.
Saenger, E.L., Thoma, G.E. and Tomkins E.A. (1968) Incidence of leukemia following treatment of hyperthyroidism: preliminary report of the Cooperative Thyrotoxicosis Follow-up Study, JAMA, 205, 147–54.
Pochin, E.E. (1960) Leukaemia following radioactive treatment of thyrotoxicosis. Br. Med. J., 2, 1545–50.
Werner, S.C., Gittleshon, A.M. and Brill, A.B. (1961) Leukemia following radioiodine therapy of hyperthyroidism. JAMA, 177, 646–9.
McCormack, K.R. and Sheline, G.E. (1963) Leukemia after radioiodine therapy for hyperthyroidism. Calif. Med., 98, 267–8.
Boyd, E., Buchanan, W.W. and Lennox, B. (1966) Damage to chromosomes by therapeutic doses of radioiodine. Lancet, 1, 977–8.
Maclntyre, M.N. and Dobyns, B.M. (1962) Anomalies in chromosomes of the circulating leukocytes in man following large doses of radioactive iodine. J. Clin. Endocrinol. Metab., 22, 1171–81.
Nofal, N.M. and Beierwaltes, W.H. (1964) Persistent chromosomal aberrations following radioiodine therapy. J. Nucl. Med., 5, 840–50.
Cantolino, S.J., Schmickel, R.D., Ball, M. et al. (1966) Persistent chromosomal aberrations following radioiodine therapy for thyrotoxicosis. N. Engl. J. Med., 275, 739–45.
Boyd, E., Ferguson-Smith, M.A., McDougall, I.R. et al. (1974) Chromosome breakage in human peripheral lymphocytes after radioactive iodine 125I therapy. Radiation Res., 57, 482–7.
Dobyns, B.M., Sheline, G.E., Workman, J.B. et al. (1974) Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the Cooperative Thyrotoxicosis Therapy Follow-up Study. J. Clin. Endocrinol. Metab., 38, 976–98.
Holm, L-E., Dahlqvist, I., Israelsson, A. et al. (1980) Malignant thyroid tumors after iodine-131 therapy. A retrospective cohort study. N. Engl. J. Med., 303, 188–91.
Holm, L-E. (1984) Malignant disease following iodine-131 therapy in Sweden, in Radiation Carcinogenesis: Epidemiology and Biological Significance, (eds J.D. Boice Jr and J.F. Fraument Jr) Raven Press, New York, pp. 263–71.
McDougall, I.R., Nelsen, T.S. and Kempson, R.L. (1981) Papillary carcinoma of the thyroid seven years after I-131 therapy for Graves’ disease. Clin. Nucl. Med., 6, 368–71.
Tomlison, C., Knowles, K.W. and McDougall, I.R. (1991) Papillary cancer in a patient treated with radioiodine for Graves’ hyperthyroidism: case report and a review of the risk. Clin. Nuc. Med., in press.
Hoffman, D.A., McConahey, W.M., Diamond, E.L. et al. (1982) Mortality in women treated for hyperthyroidism. Am. J. Epidemiol, 115, 243–54.
Hoffman, D.A. (1984) Late effects ofI-131 therapy in the United States, in Radiation Carcinogenesis; Epidemiology and Biological Significance, (eds J.D. Boice Jr and J.F. Fraument Jr), Raven Press, New York, pp. 273–80.
Robertson, J.S. and Gorman, C.A. (1976) Gonadal radiation dose and its genetic significance in radioiodine therapy of hyperthyroidism. J. Nucl. Med., 17, 826–35.
Henneman, G., Krenning, E.P. and Sankara-narayanan, K. (1986) Place of radioactive iodine in the treatment of thyrotoxicosis. Lancet, 1, 1369–72.
Chapman, E.M. (1971) Treatment of hyperthyroidism with radioactive iodine, in Nuclear Medicine, 2nd edn, (ed. W.H. Blahd), McGraw-Hill Book Company, New York, pp. 711–34.
Safa, A.M., Schumaker, O.P. and Rodriguez-Antunez, A. (1975) Long-term follow-up results in children and adolescents treated with radioactive iodine (131I) for hyperthyroidism. N. Engl. J. Med., 292, 167–71.
Gillespie, F.C., Orr, J.S. and Greig, W.R. (1970) Microscopic dose distribution from 125I in the toxic thyroid gland and its relation to therapy. Br. J. Radiol., 43, 40–7.
McDougall, I.R. and Greig, W.R. (1976) 125I therapy in Graves’ disease: long-term results in 355 patients. Ann. Intern. Med., 85, 720–3.
Lewitus, Z., Lubin, E., Rechnic, J. et al. (1971) Treatment of thyrotoxicosis with 125I and 131I. Sem. Nucl. Med., 1, 411–21.
Weidinger, P., Johnson, P.M. and Werner, S.C. (1974) Five years’ experience with iodine-125 therapy of thyrotoxic Graves’ disease. Lancet, 2, 74–7.
Siemsen, J.K., Wallack, M.S., Martin, R.B. et al. (1974) Early results of 125I therapy of thyrotoxic Graves’ disease. J. Nucl. Med., 15, 257–60.
NRCP Report No. 37 (1970) Precautions in the Management of Patients who have Received Therapeutic Amounts of Radionuclides, October 1, and second reprinting 15 March 1978.
Stoffer, S.S., Hamburger, J.I. (1976) Inadvertent 131I therapy for hyperthyroidism in the first trimester of pregnancy. J. Nucl. Med., 17, 146–9.
Mountford, P.J. and Coakley, A.J. (1989) A review of the secretion of radioactivity in human breast milk: data. quantitative analysis and recommendations. Nucl. Med. Comm., 10, 15–27.
Halstead, S. (1920) The operative story of goiter; the author’s operation, Johns Hopkins. Hosp. Rep., 19, 71–257.
Mansberger, A.R. (1988) One hundred years of surgical management of hyperthyroidism. Ann. Surg., 207, 724–9.
Mayo, C.H. (1905) Goiter: with preliminary report of one hundred and eighty-two operations on the thyroid. Trans South Surg. Gyn. Assoc, 18, 145–66.
Mayo C.H. (1908) A consideration of the mortality in one thousand operations for goiter. Trans South Surg. Gyn. Assoc, 21, 275–87.
Lahey, F.H. (1931) How much tissue should be removed in toxic goiter? Trans South Surg. Assoc, 44, 258–70.
Plummer, H.S. (1923) Results of administering iodine to patients having exophthalmic goiter. JAMA, 80, 1955.
Reeve, T.S. (1988) Surgical treatment for thyrotoxicosis. Br. J. Surg., 75, 833–4.
Green, M. and Wilson, G.M. (1964) Thyrotoxicosis treated by surgery or iodine-131 with special reference to the development of hypothyroidism. Br. Med. J., 1, 1005–10.
Bowers, R.F. (1966) Surgical treatment of hyperthyroidism: follow up of 103 cases. Am. Surgeon, 32, 89–95.
McNeil, A.D. and Thomson, J.A. (1968) Long-term follow up of surgically treated thyrotoxic patients. Br. Med. J., 3, 643–6.
Buchanan, W.W., Koutras, D.A., Crooks, J. et al. (1962) The clinical significance of the complement fixation test in thyrotoxicosis. J. Endocrinol., 24, 115–25.
Irvine, W.J., MacGregor, A.G. and Stuart, A.E. (1962) The prognostic significance of thyroid antibodies in the management of thyrotoxicosis. Lancet., 2, 843–7.
Greene, R. (1950) The significance of lym-phadenoid changes in the thyroid gland. J. Endocrinol., 7, 1–6.
Olsen, W.R., Nishiyama, R.H., Graber, L.W. et al. (1970) Thyroidectomy for hyperthyroidism. Arch. Surg., 101, 175–80.
Hedley, A.J., Flemming, C.J., Chester, M.I. et al. (1970) Surgical treatment of thyrotoxicosis. Br. Med. J., 1, 519–23.
Hedley, A.J., Ross, I.P., Beck, J.S. et al. (1971) Recurrent thyrotoxicosis after subtotal thyroidectomy. Br. Med. J., 4, 258–61.
Lee, T.C., Coffey, R.J., Currier, B.M. et al. (1982) Propranolol and thyroidectomy in the treatment of thyrotoxicosis. Ann. Surg., 195, 766–72.
Bradley, E.L. III, Di Girolamo, M. and Tar-can, Y. (1980) Modified subtotal thyroidectomy in the management of Graves’ disease. Surgery, 87, 623–9.
Ozoux, J.P., de Calan L., Portier, G. et al. (1988) Surgical treatment of Graves’ disease. Am. J. Surg., 156, 177–81.
McLarty, D.G., Alexander, W.D., Harden, R. McG. et al. (1969) Results of treatment of thyrotoxicosis after post-operative relapse. Br. Med. J., 3, 200–3.
Gould, E.A., Hirsch, E., Brecher, I. et al. (1965) Complications arising in the course of thyroidectomy. Arch. Surg., 90, 81–5.
Painter, N.S. (1960) The results of surgery in the treatment of toxic goitre: a review of 172 cases. Br. J. Surg., 48, 291–6.
Riddell, V. (1965) The selection of patients for thyroidectomy. Br. J. Surg., 52, 721–7.
Wade, J.H.S. (1965) Three major complications of thyroidectomy. Br. J. Surg., 52, 727–31.
Michie, W., Pegg, C.A.S. and Bewsher, P.D. (1972) Prediction of hypothyroidism after partial thyroidectomy for thyrotoxicosis. Br. Med. J., 1, 13–17.
McDougall, I.R. and Bayer, M.F. (1986) Should a woman taking propylthiouracil breast feed? Clin. Nucl. Med., 11, 249–50.
Michie, W., Hammer-Hodges, D.W., Pegg, C.A.S. et al. (1974) Beta-blockade and partial thyroidectomy for thyrotoxicosis. Lancet, 1, 1009–11.
Toft, A.D., Irvine, W.J., Sinclair, I. et al. (1978) Thyroid function after surgical treatment of thyrotoxicosis: a report of 100 cases treated with propranolol before operation. N. Engl. J. Med., 298, 643–7.
Jamison, M. and Done, H.J. (1979) Postop thyrotoxic crisis in a patient prepared for thyroidectomy with propranolol. Br. J. Clin. Pract., 33, 82–3.
Feek, C.M., Sawers, J.S., Irvine, W.J. et al. (1980) Combination of potassium iodide and propranolol in preparation of patients with Graves’ disease for thyroid surgery. N. Engl. J. Med., 302, 883–5.
Unger, J., Couturier, E., Durez, M. et al. (1981) Failure to reach euthyroidism with potassium iodide and propranolol in preparation of a patient with Graves’ disease for surgery, (letter). J. Endocrinol Invest., 4, 367.
Feek, C.M. and Toft, A.D. (1981) Response to previous reference. J. Endocrinol. Invest., 4, 367–8.
Plummer, H.S. (1913) The clinical and pathological relationships of hyperplastic and non hyperplastic goiter. JAMA, 61, 650–1.
Hamburger, J.I. (1987) The autonomously functioning thyroid nodule: Goetsch’s disease. Endocrine Reviews, 8, 439–47.
Goetsch, E. (1916) Functional significance of mitochondria in toxic thyroid adenomata: preliminary report. Johns Hopkins Hosp. Rep., 27, 129–33.
Goetsch, E. (1918) Newer methods in the diagnosis of thyroid disorders: pathological and clinical. N.Y. State J. Med., 18, 259–67.
Boothby, W. (1921) Adenoma of the thyroid with hyperthyroidism (thyrotoxic adenoma). Endocrinology, 5, 1–20.
Scott, R.S., Brownlie, B.E.W. and Bremner, J.M. (1978) Toxic autonomous thyroid nodule following neck irradiation. Aust. N.Z.J. Med., 8, 521–2.
Nagai, G.R., Pitts, W.C., Basso, L. et al. (1987) Scintigraphic hot nodules and thyroid cancer. Clin. Nucl. Med., 12, 123–7.
Blum, M., Shenkman, L. and Hollander, C.S. (1975) The autonomous nodule of the thyroid: correlation of patient age, nodule size and functional status. Am. J. Med. Sci., 269, 43–50.
Bransom, C.J., Talbot, C.H., Henry, L. et al. (1979) Solitary toxic adenoma of the thyroid. Br. J. Surg., 66, 590–5.
Burman, K.D., Earll, J.M., Johnson, M.C. et al. (1974) Clinical observations on the solitary autonomous thyroid nodule. Arch. Intern. Med., 134, 915–19.
Goldstein, R. and Hart, I.R. (1983) Follow-up of solitary autonomous thyroid nodules treated with 131I. N. Engl. J. Med., 309, 1473–76.
Hamburger, J.I. (1980) Evolution of toxicity in solitary non toxic autonomously functioning nodules. J. Clin. Endocrinol. Metab., 50, 1089–93.
Psarras, A., Papadopoulos, S.H., Livadas, D. et al. (1972) The single thyroid nodule. Br. J. Surg., 59, 545–8.
Ramsay, I., Marsden, P., Richardson, P.J. et al. (1972) Thyroid ‘hot’ nodules. Postgrad. Med, J., 48, 577–83.
Blum, M. and Nocero, M.A. (1974) Spontaneous resolution of a euthyroid autonomous nodule of the thyroid. Am. J. Med. Sci., 264, 49–54.
Soin, J.S., Beal, W. and Burdine, J.A. (1974) Disappearance of autonomous thyroid nodule under TSH stimulation. J. Nucl. Med., 15, 1209–11.
Kammer, H. and Loveless, M.D. (1978) Disappearance of a hyperfunctioning thyroid nodule following TSH stimulation. J. Nucl. Med., 19, 1149–50.
McCormack, K.R. and Sheline, G.E. (1967) Long-term studies of solitary autonomous thyroid nodules. J. Nucl. Med., 8, 701–8.
Silverstein, G.E., Burke, G. and Cogan, R. (1967) The natural history of the autonomously hyperfunctioning thyroid nodule. Ann. Intern. Med., 67, 539–48.
Wiener, J.D. and De Vries, A.A.A. (1979) On the natural history of Plummer’s disease. Clin. Nucl. Med., 4, 181–90.
Hamburger, J.I. and Taylor, C.I. (1979) Transient thyrotoxicosis associated with acute hemorrhagic infarction of autonomously functioning thyroid nodule. Ann. Intern, Med., 91, 406–9.
Abe, K., Konno, M., Sato, T. et al. (1980) Hyperfunctioning thyroid nodules in children. Am. J. Dis. Child, 134, 961–3.
Popma, B.H., Cloutier, M.D. and Hayles, A.B. (1973) Thyroid nodule producing T3 toxicosis in a child. Mayo Clin. Proc., 48, 273–5.
Shambaugh, G.E., Quinn, J.L., Oyasu, R. et al. (1974) Disparate thyroid imaging. Combined studies with pertechnetate Tc-99m and radioactive iodine. JAMA, 228, 866–9.
Barth, J.D., Bakker, W.H. and Henneman, G. (1978) Discrepancies between iodine and technetium thyroid scintigraphy. JAMA, 240, 463–4.
Erjavic, M., Mavrin, T., Auersperg, M. et al. (1977) Comparative accumulation of 99mTc and 131I in thyroid nodules: case report. J. Nucl. Med., 18, 346–7.
Sterling, K., Refetoff, S., Selenkow, H.A. (1970) Thyrotoxicosis due to elevated serum triiodothyronine levels. JAMA, 213, 571–5.
Larsen, P.R. (1972) Triiodothyronine, review of recent studies of its physiology and pathophysiology in man. Metabol., 21, 1073–92.
Means, J.H. (1970) Thyroidology 1950 The Pharos Nov.
Miller, J.M. and Hamburger, J.I. (1965) The thyroid scintigram. 1. The hot nodule. Radiol., 84, 66–73.
Landgarten, S. and Spencer, R.P. (1973) A study of the natural history of ‘hot’ thyroid nodules. Yale J. Biol. Med., 46, 259–63.
Perlmutter, M. and Slater, S.L. (1956) Which nodular goiter should be removed? N. Engl. J. Med., 255, 65–71.
Livadas, D.P., Kotoulas, O.B., Bouropoulou, V. et al. (1977) The coexistence of thyroid malignancy with autonomous hot nodules of the thyroid. Clin. Nucl. Med., 2, 350–4.
Kendall, L.W. and Condon, R.E. (1969) Prediction of malignancy in solitary thyroid nodules. Lancet, 1, 1071–3.
Becker, F.O., Economou, P.G. and Schwartz, T.B. (1963) The occurrence of carcinoma in ‘hot’ thyroid nodules. Ann. Intern. Med., 58, 877–82.
Sandler, M.P., Fellmeth, B., Salhany, K.E. et al. (1988) Thyroid carcinoma masquerading as a solitary benign hyperfunctioning nodule. Clin. Nucl. Med., 13, 410–15.
Eyre-Brook, I.A. and Talbot, C.H. (1982) The treatment of autonomously functioning thyroid nodules. Br. J. Surg., 69, 577–9.
Skillern, P.G., McCullagh, E.P. and Clamen, M. (1962) Radioiodine in diagnosis and therapy of hyperthyroidism. Arch. Intern. Med., 110, 888–97.
Gorman, C.A. and Robertson, J.S. (1978) Radiation dose in the selection of 131I or surgical treatment for toxic thyroid adenoma. Ann. Intern. Med., 89, 85–90.
Ratcliffe, G.E., Cooke, S., Fogelman, I. et al. (1986) Radioiodine treatment of solitary functioning thyroid nodules. Br. J. Radiol., 59, 385–7.
Ross, D.S., Ridgway, E.C. and Daniels, G.H. (1984) Successful treatment of solitary toxic nodules with relatively low-dose iodine-131, with low prevalence of hypothyroidism. Ann. Intern. Med., 101, 488–90.
Wiener, J.D. (1985) Long-term follow-up after iodine-131 treatment for Plummer’s disease (autonomous goiter). Clin. Nucl. Med., 10, 256–9.
Hamburger, J.I. and Hamburger, S.W. (1985) Diagnosis and management of large toxic multinodular nodules. J. Nucl. Med., 26, 888–92.
Hamburger, J.I. and Meier, D.A. (1971) Cancer following treatment of an autonomously functioning thyroid nodule with sodium iodideI-131. Arch. Surg., 103, 762–4.
Blum, M., Kranjac, T., Park, C.M. et al. (1976) Thyroid storm after cardiac angiography with iodinated contrast medium: occurrence in a patient with a previously euthyroid autonomous nodule of the thyroid. JAMA, 235, 2324
Jensen, M.D., Gharib, H., Naessens, J.M. et al. (1986) Treatment of toxic multinodular goiter (Plummer’s disease): surgery or radioiodine? World]. Surg., 10, 673–80.
Charkes, N.D. (1972) Graves’ disease with functioning nodules (Marine Lenhart syndrome). J. Nucl. Med., 13, 885–92.
Cooper, D.S. (1988) Thyroid hormone and the skeleton: a bone of contention. JAMA, 259, 3137–41.
Hay, I.D. (1988) Immunometric thyrotropin assays: current roles and future directions. Mayo Clin. Proc., 63, 1230–3.
Ross, D.S. (1988) Subclinical hyperthyroidism: possible danger of overzealous thyroxine replacement therapy. Mayo Clin. Proc., 63, 1223–9.
Fallon, M.D., Perry, H.M. III, Bergfeld, M. et al. (1983) Exogenous hyperthyroidism with osteoporosis. Arch. Intern. Med., 143, 442–4.
Paul, T.L., Kerrigan, J., Kelly, A.M. et al. (1988) Long-term L-thyroxine is associated with decreased hip bone density in premenopausal women. JAMA, 259, 3137–41.
Gorman, C.A., Wahner, H.W. and Tauxe, W.N. (1969) Metabolic malingerers. Patients who deliberately induce or perpetuate a hypermetabolic or hypometabolic state. Am. J. Med., 48, 708–14.
Rose, E., Sanders, T.P., Webb, W.L. et al. (1969) Occult factitial thyrotoxicosis. Thyroxine kinetics and psychological evaluation in three cases. Ann. Intern. Med., 71, 309–15.
Harvey, R.F. (1973) Thyroxine ‘addicts’. Br. Med. J., 2, 35–6.
Mariotti, S., Martino, E., Cupini, C. et al. (1982) Low serum thyroglobulin as a clue to the diagnosis of thyrotoxicosis factitia. N. Engl. J. Med., 307, 410–12.
Kinney, J.S., Hurwitz, E.S., Fishbein, D.B. et al. (1988) Community outbreak of thyrotoxicosis: epidemiology, immunogenetic charac-teristics, and long-term outcome. Am. J. Med., 84, 10–18.
Hedberg, C.W., Fishbein, D.B., Janssen, R.S. et al. (1987) An outbreak of thyrotoxicosis caused by the consumption of bovine thyroid gland in ground beef. N. Engl. J. Med., 316, 993–8.
Shimaoka, K., Van Herle, A.J. and Dindo-gau, A. (1976) Thyrotoxicosis secondary to involvement of the thyroid gland with malignant lymphoma. J. Clin. Endocrinol. Metab., 43, 64–8.
Erikson, M., Ajmani, S.K. and Mallette, L.E. (1977) Hyperthyroidism from thyroid metastasis of pancreatic adenocarcinoma. JAMA, 238, 1276–8.
Rosen, I.B., Strawbridge, H.G., Walfish, P.G. et al. (1978) Malignant pseudothyroidi-tis: a new clinical entity. Am. J. Surg., 136, 445–9.
Tibaldi, J.M., Shapiro, L.E. and Mahadevia, P.S. (1986) Thyroiditis mimicked by metastatic carcinoma to the thyroid. Mayo Clin. Proc., 61, 399–400.
Crapo, L. (1989) personal communication.
Watts, N.B. and Sewell, C.W. (1988) Carcinomatous involvement of thyroid presenting as subacute thyroiditis. Am. J. Med. Sci., 296, 126–8.
Oppenheim, A., Miller, M., Anderson, G.H. et al. (1983) Anaplastic thyroid cancer presenting with hyperthyroidism. Am. J. Med., 75, 702–4.
Kurtz, S.C. and Aber, R.C. (1982) Potassium iodide as a cause of prolonged fever. Arch. Intern. Med., 142, 1543–4.
Rasmussen, H. (1955) Iodide hypersensitivity in the etiology of periarteritis nodosa. J. Allergy Clin. Immunol, 26, 394–407.
Curd, J.G., Milgrom, H., Stevenson, D.D. et al. (1979) Potassium iodide sensitivity in four patients with hypocomplementemic vasculitis. Ann. Intern. Med., 91, 853–7.
Ingbar, S.H. (1972) Autoregulation of the thyroid: response to iodide excess and depletion. Mayo Clin. Proc., 47, 814–23.
Sternthal, E., Lipworth, L., Stanley, B. et al. (1980) Suppression of thyroid radioiodine uptake by various doses of stable iodine. N. Engl. J. Med., 303, 1083–8.
Braverman, L.E., Ingbar, S.H., Vagenakis, A.G. et al. (1971) Enhanced susceptibility to iodine myxedema in patients with Hashimoto’s disease. J. Clin. Endocrinol. Metab., 32, 515–21.
Braverman, L.E., Woeber, K.A. and Ingbar, S.H. (1969) Induction of myxedema by iodide in patients euthyroid after radioiodine or surgical treatment of hyperthyroidism. N. Engl. J. Med., 281, 816–21.
Vagenakis, A.G., Wang, C., Burger, A. et al. (1972) Iodide-induced thyrotoxicosis in Boston. N. Engl, J. Med., 287, 523–7.
Wilson, G.M. (1964) Two Scottish doctors and the English bronchocele. Scot. Med. J., 9, 96–102.
Stewart, J.C. and Vidor, G.I. (1976) Thyrotoxicosis induced by iodine contamination of food — a common unrecognised condition. Br. Med. J., 1, 372–5.
Fradkin, J.E. and Wolff, J. (1983) Iodide-induced thyrotoxicosis. Medicine, 62, 1–20.
Martino, E., Aghini-Lombardi, F., Marriotti, S. et al. (1987) Amiodarone: a common source of iodine-induced thyrotoxicosis. Horm. Res., 26, 158–71.
Blum, M., Weinberg, U., Shenkman, L. et al. (1974) Hyperthyroidism after iodinated contrast material. N. Engl. J. Med., 291, 24–5.
Fairhurst, B.J. and Naqvi, N. (1975) Hyperthyroidism after cholecystography. Br. Med. J., 2, 630.
Shetty, S.P., Murthy, G.G., Shreeve, W. et al. (1974) Hyperthyroidism after pyelography. N. Engl. J. Med., 292, 682.
Short, R. (1909) Jodoform and thyroidism. Br. Med. J., 2, 1469.
Miller, H.A., Farley, J.A. and Major, D.A. (1981) Topical iodine and hyperthyroidism. Ann. Intern. Med., 95, 121.
Reith, P.E. and Granner, D.K. (1985) Iodine-induced thyrotoxicosis in a woman with multinodular goiter taking levothyroxine. Arch. Intern. Med., 145, 355–6.
Edmunds, H.T. (1955) Acute thyroiditis from potassium iodide. Br. Med. J., 1, 354.
Melmed, S., Nademanee, K., Reed, A.W. et al. (1981) Hyperthyroxinemia with bradycardia and normal thyrotropin secretion after chronic amiodarone administration. J. Clin. Endocrinol. Metab., 53, 997–1001.
Nademanee, K., Singh, B.N., Hendrickson, J.A. et al. (1982) Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy. Circulation, 66, 202–11.
Martino, E., Aghini-Lombardi, F., Lippi, F. et al. (1985) Twenty-four hour radioactive iodine uptake in 35 patients with amiodarone associated thyrotoxicosis. J. Nucl. Med., 26, 1402–7.
Livadas, D.P., Koutras, D.A., Souvatzoglou, A. et al. (1977) The toxic effects of small iodine supplements in patients with autonomous thyroid nodules. Clin. Endocrinol., 7, 121–7.
Martino, E., Safran, M., Aghini-Lombardi, F. et al. (1984) Environmental iodine intake and thyroid dysfunction during chronic amiodar-one therapy. Ann. Intern. Med., 101, 28–34.
Gammage, M.D. and Franklyn, J.A. (1987) Amiodarone and the thyroid. Quart. J. Med. New Series, 62, 83–6.
Newnham, H.H., Chosich, N., Topliss, D.J. et al. (1988) Amiodarone-induced hyperthyroidism: assessment of predictive value of biochemical testing and response to combined therapy using propylthiouracil and potassium perchlorate. Aust. N.Z. J. Med., 18, 37–44.
Mechlis, S., Lubin, E., Laor, J. et al. (1988) Amiodarone-induced thyroid gland dysfuc-tion. Am. J. Cardiol, 59, 833–5.
Miaskiewicz, S.L., Amico, J.A., Follansbee, W.P. et al. (1987) Amiodarone-associated thyrotoxicosis masquerading as painful thyroiditis. Ann. Intern. Med., 107, 118–19.
Wimpfheimer, C., Staubli, M., Schadelin, J. et al. (1982) Prednisone in amiodarone-induced thyrotoxicosis. Br. Med. J., 284, 1835–6.
Woodruff, J.D., Rauh, J.T. and Markley, R.L. (1966) Ovarian struma. Obstet. Gynecol., 27, 194–202.
Janovski, N.A. and Paramanandhan, T.L. (1973) Ovarian Tumors, Vol 4, Major Problems in Obstetrics and Gynecology, WB Saunders Company, Philadelphia, pp. 89–90.
Kempers, R.D., Dockerty, M.B., Hoffman, D.L. et al. (1970) Struma ovarii — ascitic, hyperthyroid and asymptomatic syndromes. Ann. Intern. Med., 72, 883–93.
Pardo-Mindan, F.J. and Vazquez, J.J. (1983) Malignant struma ovarii. Light and electron microscopic study., Cancer, 51, 337–43.
McDougall, I.R., Krasne, D., Hanberry, J.W. et al. (1989) Malignant struma ovarii presenting as paraparesis from a spinal metastasis. J. Nucl. Med., 30, 407–11.
Smith, F.G. (1946) Pathology and physiology of struma ovarii. Arch. Surg., 53, 603–26.
Brown, W.W., Shetty, K.R. and Rosenfeld, P.S. (1973) Hyperthyroidism due to struma ovarii: demonstration by radioiodine scan. Acta Endocrinol., 73, 266–72.
Federman, D.D. (1964) Hyperthyroidism due to functioning metastatic carcinoma of the thyroid. Medicine, 43, 267–74.
Ober, K.P., Cowan, R.J., Sevier, R.E. et al. (1987) Thyrotoxicosis caused by functioning metastatic thyroid carcinoma. A rare and elusive cause of hyperthyroidism with low radioactive iodine uptake. Clin. Nucl Med., 12, 345–8.
Citrin, D.L., Pederson, J., Rose, D.B. et al. (1978) Radiation-induced carcinoma of the thyroid with severe thyrotoxicosis. Wisc. Med. J., 77, 597–9.
Studer, H., Veraguth, P. and Wyss, F. (1961) Thyrotoxicosis due to a solitary hepatic metastasis of thyroid carcinoma. J.Clin. Endocrinol. Metab., 21, 1334–8.
Chapman, C.N., Sziklas, J.J., Spencer, R.P. et al. (1984) Hyperthyroidism with metastatic follicular thyroid carcinoma. J. Nucl. Med., 25, 466–8.
Sung, L.C. and Cavalieri, R.R. (1973) T3 toxicosis due to metastatic thyroid carcinoma. J. Clin. Endocrinol. Metab., 36, 215–17.
Pont, A. Spratt, D. and Shin, J.B. (1982) T3 toxicosis due to nonmetastatic follicular carcinoma of the thyroid. West J. Med., 136, 255–8.
Cerletty, J.M. and Listwan, W.J. (1979) Hyperthyroidism due to functioning metastatic thyroid carcinoma. Precipitation of thyroid storm with therapeutic radioactive iodine. JAMA, 242, 269–70.
Weintraub, B.D., Gershengorn, M.C., Kourides, M.C. et al. (1981) Inappropriate secretion of thyroid-stimulating hormone. Ann. Intern. Med., 95, 339–51.
Brenner-Gati, L. and Gershengorn, M.C. (1985) Thyroid-stimulating hormone-induced hyperthyroidism, in The Pituitary Gland, (ed. H. Imura), Raven Press, New York, pp. 467–500.
Tolis, G., Bird, C., Bertrand, G. et al. (1978) Pituitary hyperthyroidism: case report and review of the literature. Am. J. Med., 64, 177–81.
Smallridge, R.C. and Smith, C.E. (1983) Hyperthyroidism due to thyrotropin-secreting pituitary tumors. Arch. Intern. Med., 143, 503–7.
Kourides, I.A., Ridgway, E.C., Weintraub, B.D. et al. (1977) Thyrotropin-induced hyperthyroidism: use of alpha and beta subunit levels to identify patients with pituitary tumors. J. Clin. Endocrinol. Metab., 45, 534–43.
Kourides, I.A., Pekonen, F. and Weintraub, B.D. (1980) Absence of thyroid-binding immunoglobulins in patients with thyrotropin-mediated hyperthyroidism. J.Clin. Endocrinol. Metab., 51, 271–4.
Yovos, J.G., Falko, J.M., O’Dorisio, T.M. et al. (1981) Thyrotoxicosis and a thyrotropin-secreting pituitary tumor causing unilateral exophthalmos. J. Clin. Endocrinol. Metab., 53, 338–43.
Spanheimer, R.G., Bar, R.S. and Hayford, J.C. (1982) Hyperthyroidism caused by inappropriate thyrotropin hypersecretion: studies in patients with selective pituitary resistance to thyroid hormone. Arch. Intern. Med., 142, 1283–6.
Gharib, H., Carpenter, P.C., Scheithauer, B.W. et al. (1982) The spectrum of inappropriate pituitary thyrotropin secretion associated with hyperthyroidism. Mayo Clin. Proc., 57, 556–63.
Refetoff, S., DeWind, L.T. and DeGroot, L.J. (1967) Familial syndrome combining deaf-mutism, stippled epiphysis, goiter and abnormally high PBI: possible target refractoriness to thyroid hormone. J. Clin. Endocrinol. Metab., 27, 279–94.
Refetoff S., Salazar, A., Smith, T.J. et al. (1983) The consequences of inappropriate treatment because of failure to recognize the syndrome of pituitary and peripheral resistance to thyroid hormone. Metabolism, 32, 822–34.
Hughes, I.A., Ichikawa, K., DeGroot, L.J. et al. (1987) Non-adenoma tous inappropriate TSH hypersecretion and euthyroidism requires no treatment. Clin. Endocrinol., 27, 475–83.
Tisne, L. et al. (reference in Spanish, interested readers see Higgins, H.P. et al. [403]).
Odell W.D., Bates, R.W., Rivlin, R.S. et al. (1963) Increased thyroid function without clinical hyperthyroidism in patients with choriocarcinoma. J. Clin. Endocrinol. Metab., 23, 658–64.
Hershman, J.M. and Higgins, H.P. (1971) Hydatidiform mole — a cause of clinical hyperthyroidism. N. Engl. J. Med., 284, 573–7.
Higgins H.P., Hershman, J.M., Kenimer, J.G. et al. (1975) The thyrotoxicosis of hydatidiform mole. Ann. Intern. Med., 83, 307–11.
Soutter, W.P., Norman, R. and Green-Thompson, R.W. (1981) The management of choriocarcinoma causing severe thyrotoxicosis. Two case reports. Br. J. Obstet. Gynaecol., 88, 938–43.
Hershman, J.M. (1981) Hyperthyroidism caused by trophoblastic tumors. Thyroid Today, 4 (1), (ed. J. Oppenheimer).
Rajatanavin, R., Chailurkit, L-O., Srisupan-dit, S. et al. (1988) Trophoblastic hyperthyroidism: clinical and biochemical features in five cases. Am. J. Med., 85, 237–241.
Steigbigel, N.H. (1964) Metastatic embryonal carcinoma of the testis asssociated with elevated plasma TSH-like activity and hyperthyroidism. N. Engl, J. Med., 271, 345–9.
Karp, P.J., Hershman, J.M., Richmond, S. et al. (1973) Thyrotoxicosis from molar thyrotropin. Arch. Intern. Med., 132, 432–6.
Stromberg, P., Ratcliffe, J.G., Trotter, J., et al. (1981) Teratoma of the testis and hyperthyroidism. Scot. Med. J., 26, 346–7.
Safa, A.M., Schumaker, P. and Rodriguez-Antunez, A. (1975) Long-term follow-up results in children and adolescents treated with radioiodine (131I) for hyperthyroidism. N. Engl. J. Med., 292, 167–71.
Hamburger, J.I. (1985) Management of hyperthyroidism in children and adolescents. J. Clin. Endocrinol. Metab., 60, 1019–24.
Barnes, H.V. and Blizzard, R.M. (1977) Antithyroid drug therapy for toxic diffuse goiter (Graves’) disease: thirty years’ experience in children and adolescents. J. Pediatr., 91, 313–20.
Freitas, J.E., Swanson, D.P., Gross, M.D. et al. (1979) Iodine-131: optimal therapy for hyperthyroidism in children and adolescents. J. Nucl Med., 20, 847–50.
Crile, G. Jr and Schumacher, O.P. (1965) Radioactive iodine treatment of Graves’ disease: results of 32 children under 16 years of age. Am. J. Dis. Child, 110, 501–4.
Levy, W.J., Schumacher, O.P. and Gupta, M. (1988) Treatment of childhood Graves’ disease. Clev. Clin. J. Med., 55, 373–82.
Buckingham, B.A., Costin, G., Roe, T.F. et al. (1981) Hyperthyroidism in children: a reevaluation of treatment. Am. J. Dis. Child, 135, 112–17.
Hayles, A.B. and Zimmerman, D. (1986) Graves’ disease in childhood, in The Thyroid, 5th edn, (eds S.H. Ingbar and L.E. Braverman) Lippincott, Philadelphia, pp. 1414–23.
McArthur, R.G. (1978) Hyperthyroidism in childhood. Thyroid Today, 1 (5), (ed. J.H. Oppenheimer).
Marks, P. and Ashraf, H. (1978) Apathetic hyperthyroidism with hypomagnesemia and raised alkaline phosphatase concentration. Br. Med. J., 1, 821–2.
Lahey, F.H. (1931) Non-activated (apathetic) type of hyperthyroidism. N. Engl. J. Med., 204, 747–8.
Lahey, F.H. (1931) Apathetic thyroidism. Ann. Surg., 93, 1021–30.
Tibaldi, J.M., Barzel, U.S., Albin, J. et al. (1986) Thyrotoxicosis in the very old. Am. J. Med., 81, 619–22.
Ronnon-Jensen, V. and Kirkegaard, C. (1973) Hyperthyroidism — a disease of old age. Br. Med. J., 1, 41–3.
Davis, P.J. and Davis, F.B. (1974) Hyperthyroidism in patients over the age of 60 years. Medicine, 53, 161–81.
Bartels, E.C. (1965) Hyperthyroidism in patients over 65. Geriatrics, 20, 459–62.
Thomas, F.B., Mazzaferri, E.L. and Skillman, T.G. (1970) Apathetic thyrotoxicosis: a distinctive clinical and laboratory entity. Ann. Intern. Med., 72, 679–85.
Kawabe, T., Komiya, I., Endo, T. et al. (1979) Hyperthyroidism in the elderly. J. Am. Geriatric. Soc, 27, 152–5.
Caplan, R.H., Glaser, J.E., Davis, K. et al. (1978) Thyroid function tests in elderly hyperthyroid patients. J. Am. Geriatric Soc., 26, 116–20.
Burrow, G.N. (1985) The management of thyrotoxicosis in pregnancy. N. Engl. J. Med., 313, 562–5.
Burrow, G.N. (1978) Hyperthyroidism during pregnancy. N. Engl. J. Med., 298, 150–3.
Burrow, G.N. (1982) Thyroid diseases, in Medical Complications During Pregnancy, 2nd edn, (eds G.N. Burrow and T.F. Ferris), W. B. Saunders, London, Philadelphia, Toronto, pp. 187–214.
Ramsay, I. (1983) Drug treatment of thyroid and adrenal disease during pregnancy, in Clinical Pharmacology in Obstetrics, (ed. P. Lewis), Wright PSG, Bristol, London, Boston, pp. 232–50.
Aboul-Khair, S.A., Crooks, J., Turnbull, A.C. et al. (1964) The physiological changes in thyroid function during pregnancy. Clin. Sci., 27, 195–207.
Caplan, R.H. and Wickus, G. (1979) Goiter and plasma inorganic iodide concentration in pregnancy: a reassessment. JAMA, 242, 352–3.
Long, T.J., Felice, M.E. and Hollingsworth, D.R. (1985) Goiter in pregnant teenagers. Am. J. Obstet. Gynecol, 152, 670–4.
Levy, R.P., Newman D.M., Rejali, L.S. et al. (1980) The myth of goiter in pregnancy. Am. J. Obstet. Gynecol, 137, 701–3.
McDougall, I.R. (1989) Maternal-fetal thyroid hormone metabolism and hyperthyroidism, in Endocrine Disorders in Pregnancy, (eds S.A. Brody and K. Ueland), Appleton and Lange, Norwalk Connecticut/San Mateo, California, pp. 151–64.
Hardisy, C.A. and Munro, D.S. (1983) Serum long acting thyroid stimulator protector in pregnancy complicated, by Graves’ disease. Br. Med. J., 286, 554–5.
Momotani N., Ito, K., Hamada, N. et al. (1984) Maternal hyperthyroidism and congenital malformation in the offspring. Clin. Endocrinol., 20, 695–700.
Montoro, M. and Mestman, J.H. (1981) Graves’ disease and pregnancy. N. Engl. J. Med., 305, 48.
Mujtaba, Q. and Burrow, G.N. (1975) Treatment of hyperthyroidism in pregnancy with propylthiouracil and methimazole. Obstet. Gynecol, 46, 282–6.
Cheron, R.G., Kaplan, M.M., Larsen, P.R. et al. (1981) Neonatal thyroid function after propylthiouracil therapy for maternal Graves’ disease. N. Engl. J. Med., 304, 525–8.
Rubin, P.C. (1981) Beta-blockers in pregnancy. N. Engl. J. Med., 305, 1323–6.
Galina, M.P., Avnet, N.L. and Einhorn, A. (1962) Iodides during pregnancy: an apparent cause of neonatal death. N. Engl. J. Med., 267, 1124–7.
Howe, P. and Francis, H.H. (1962) Pregnancy and thyrotoxicosis. Br. Med. J., 2, 817–62.
Menon V., McDougall, W.W. and Leatherdale, B.A. (1982) Thyrotoxic crisis following eclampsia and induction of labour. Postgrad. Med. J., 58, 286–7.
Derksen, R.H.W.M., van de Weil, A., Poortman, J. et al. (1984) Plasma-exchange in the treatment of severe thyrotoxicosis in pregnancy. Eur. J. Obstet. Gynec. Reprod. Biol, 18, 139–48.
Williams, R.H., Kay, G.A. and Jandorf, B.J. (1944) Thiouracil. Its absorbtion, distribution, and excretion. J. Clin. Invest., 23, 613–27.
Kampman, J.P., Johansen, K., Hansen, J.M. et al. (1980) Propylthiouracil in human milk. Revision of a dogma. Lancet, 1, 736–8.
McKenzie, J.M. and Zakarija, M. (1978) Pathogenesis of neonatal Graves’ disease. J. Endocrinol. Invest., 2, 182–9.
Robinson, A.C., O’Connor, M.K., Tempany, E. et al. (1982) Thyroid pertechnetate scan in neonatal hyperthyroidism. Ir. J. Med. Sci., 151, 22–3.
Cove, D.H. and Johnston, P. (1985) Fetal hyperthyroidism: experience of treatment of four siblings. Lancet, 1, 430–2.
Wilson, D.M., Hopper, A.O., McDougall, I.R. et al. (1982) Serum free thyroxine values in term, premature and sick infants. J. Pediatr., 101, 113–17.
Robinson, D.C., Hall, R. and Munro, D.S. (1969) Graves’ disease, an unusual complication: raised intracranial pressure due to premature fusion of skull sutures. Arch. Dis. Child, 44, 252–7.
Riggs, W., Wilroy, R.S. and Etteldorf, J.N. (1971) Neonatal hyperthyroidism with accelerated skeletal maturation craniosynos-tosis and brachydactyly. Radiol., 105, 621–5.
Macklin, J.F., Canary, J.J. and Pittman, C.S. (1974) Thyroid storm and its management. N. Engl. J. Med., 291, 1396–8.
Newmark, S.R., Himathongkam, T. and Shane, J.M. (1974) Hyperthyroid crisis. JAMA, 230, 592–3.
Urbanic, R.C. and Mazzaferri, E.L. (1978) Thyrotoxic crisis and myxedema coma. Heart Lung, 7, 435–47.
Mazzaferri, E.L. and Skillman, T.G. (1969) Thyroid storm: a review of 22 episodes with special emphasis on the use of guanethidine. Arch. Intern. Med., 124, 684–90.
Roizen, M. and Becker, C.E. (1971) Thyroid storm. Calif. Med., 115, 5–9.
Troen, P., Taymor, R.C. and Goldberg, B.I. (1951) Thyroid crisis associated with diabetic coma. N. Engl. J. Med., 244, 394–8.
Hanscom, D.H. and Ryan, R.J. (1957) Thyroid crisis and diabetic ketoacidosis. N. Engl. J. Med., 257, 697–701.
Ingbar, S.H. (1975) When to hospitalize the patient with thyrotoxicosis. Hosp. Pract., Jan, 45–53.
Brooks, M.H. and Waldstein, S.S. (1980) Free thyroxine concentrations in thyroid storm. Ann. Intern. Med., 93, 694–7.
Goldfarb, C.R., Varma, C. and Roginsky, M. (1980) Diagnosis in delirium: prompt confirmation of thyroid storm. Clin. Nucl. Med., 5, 66.
Wu, S-Y., Chopra, I.J., Solomon, D.H. et al. (1978) The effect of repeated doses of ipodate (oragrafin) in hyperthyroidism. J. Clin. Endocrinol. Metab., 47, 1358–62.
Hellman, R., Kelly, K.L. and Mason, W.D. (1977) Propranolol for thyroid storm (letter), N. Engl. J. Med., 297, 671–2.
Ashkar, F.S., Katims, R.B., Smoak, W.M. III, et al. (1970) Thyroid storm treatment with blood exchange and plasmapheresis. JAMA, 214, 1275–9.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1992 I. Ross McDougall
About this chapter
Cite this chapter
McDougall, I.R. (1992). Hyperthyroidism. In: Thyroid Disease in Clinical Practice. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-2881-8_5
Download citation
DOI: https://doi.org/10.1007/978-1-4899-2881-8_5
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-19-520936-5
Online ISBN: 978-1-4899-2881-8
eBook Packages: Springer Book Archive